hero image

Biogen Reports Third Quarter 2022 Results

October 25, 2022 News Release
December 6, 2022
Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Zuranolone is being evaluated as a short course, rapid-acting, oral medication for major depressive disorder (MDD) and postpartum depression (PPD)     Cambridge, Mass. – Dec. 6, 2022 – Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics (Nasdaq: SAGE) announced the completion of the rolling submission

December 5, 2022
European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS

SOD1-ALS is a rare, genetic form of ALS, 1 comprising approximately 2% of people with ALS 2 If approved, tofersen would be the first treatment to target a genetic cause of ALS CAMBRIDGE, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the European Medicines Agency